← Back

Liaoning Cheng Da Co Ltd

Liaoning Cheng Da Co., Ltd. operates in pharmaceuticals and healthcare, financial investment, trading, and energy development in China and internationally. Its activities include importing and exporting textiles and clothing, trading bulk commodities such as coal, steel, and aquatic products, and oil shale mining, shale oil production, and sales. The company also provides financial services through securities, insurance, and funds; produces human rabies vaccines and inactivated Japanese encephalitis vaccines; and engages in medical industry investment, medical enterprise management consulting, and computer software and hardware development, consulting, transfer, and technical services, as well as the sale of medical equipment. Founded in 1991, it is headquartered in Dalian, China.

Price · split & dividend adjusted
News & notes moving 600739.CG
600739.CG▲4

Liaoning Chengda first-half net profit 1.62 billion yuan, up 125.77% year on year

Liaoning Chengda disclosed its semi-annual report on August 30. In the first half of 2026, it achieved operating revenue of 4.411 billion yuan, down 13.56% year on year. Net profit attributable to shareholders of the listed company was 1.62 billion yuan, up 125.77% year on year. Basic earnings per share were 1.0642 yuan. During the reporting period, the main reason for the change in revenue was a year-on-year decline in the scale of bulk commodity trading, while the main reason for the increase in net profit was a year-on-year increase in the company's investment income.
600739.CG ▲
证券时报·20dRead more →
600739.CG▼2

Liaoning Chengda shareholder Guangxi Xinyixin pledges 12.96 million shares, cumulative pledge exceeds 70% of its holdings

Liaoning Chengda shareholder Guangxi Xinyixin has pledged 12.96 million shares, representing 9.94% of its holdings and 0.85% of the company's total share capital. As of the announcement date, Guangxi Xinyixin's cumulative pledged shares amount to 99.28 million shares, accounting for 76.18% of its holdings and 6.52% of the company's total share capital. In the first quarter of 2026, Liaoning Chengda achieved revenue of 1.991 billion yuan and net profit attributable to the parent company of 551 million yuan.
600739.CG ▼
财中社·64dRead more →
600739.CG▲2

Liaoning Chengda expects first-half 2026 net profit to rise 102% to 138%

Liaoning Chengda disclosed its earnings forecast, estimating net profit attributable to shareholders of the parent company for the first half of 2026 at 1.452 billion to 1.71 billion yuan, a year-on-year increase of 102.28% to 138.32%. Net profit after deducting non-recurring items is expected to be 1.455 billion to 1.714 billion yuan, up 104.39% to 140.71% year-on-year. The company stated that the main reason for the significant growth in performance is the year-on-year increase in investment income. Liaoning Chengda's business spans four major segments: pharmaceutical and healthcare, financial investment, domestic and international trade, and energy development.
600739.CG ▲
中国证券报·67dRead more →
600739.CG3

Liaoning Chengda Shareholder Guangxi Xinyixin Releases Pledge on 15.45 Million Shares

Liaoning Chengda shareholder Guangxi Xinyixin Business Services Co., Ltd. has released the pledge on 15.45 million shares, representing 11.86% of its holdings and 1.01% of the company's total share capital. Following the release, Guangxi Xinyixin's cumulative pledged shares stand at 88.77 million, accounting for 68.12% of its holdings and 5.83% of the company's total share capital. In the first quarter of 2026, Liaoning Chengda achieved revenue of 1.991 billion yuan and net profit attributable to the parent company of 551 million yuan.
600739.CG
财中社·75dRead more →
© 2026 MarketDXAsset